---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-196671"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2022-07-19T23:59:59+00:00"
generated_at: "2026-06-24T11:59:52.519028+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INOVIO cuts 18% workforce (55 employees) and 86% of contractors to extend cash runway to Q3 2024

## Summary
- Headcount reduced by 55 employees (18% of full-time staff) and 86% of contractor agreements terminated.
- Expected to reduce operating expenses by ~30% over 18 months; cash runway extended into Q3 2024.
- One-time pre-tax charge of $1.6 million in Q3 2022; cash payments substantially completed by Sept 30, 2022.
- Focus shifts to heterologous boost strategy for COVID-19 vaccine (INO-4800) and HPV programs; key data readouts later in 2022.

## SEC filing metadata
- accession: 0001193125-22-196671
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2022-07-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312522196671/0001193125-22-196671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312522196671/d382508d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-196671
- JSON: https://secwatch.observer/filing/0001193125-22-196671.json
- Plain text: https://secwatch.observer/filing/0001193125-22-196671.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.